User profiles for Mona Bafadhel
 | Mona BafadhelUniversity of Oxford Verified email at ndm.ox.ac.uk Cited by 9588 |
Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers
M Bafadhel, S McKenna, S Terry, V Mistry… - American journal of …, 2011 - atsjournals.org
Rationale: Exacerbations of chronic obstructive pulmonary disease (COPD) are heterogeneous
with respect to inflammation and etiology. Objectives: Investigate biomarker expression …
with respect to inflammation and etiology. Objectives: Investigate biomarker expression …
[HTML][HTML] Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts
…, CF Vogelmeier, J Cole, M Bafadhel… - … England Journal of …, 2023 - Mass Medical Soc
Background In some patients with chronic obstructive pulmonary disease (COPD), type 2
inflammation may increase exacerbation risk and may be indicated by elevated blood …
inflammation may increase exacerbation risk and may be indicated by elevated blood …
[HTML][HTML] Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
Background Multiple early reports of patients admitted to hospital with COVID-19 showed
that patients with chronic respiratory disease were significantly under-represented in these …
that patients with chronic respiratory disease were significantly under-represented in these …
Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission
Despite substantial progress in reducing the global impact of many non-communicable
diseases, including heart disease and cancer, morbidity and mortality due to chronic respiratory …
diseases, including heart disease and cancer, morbidity and mortality due to chronic respiratory …
Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial
M Bafadhel, S McKenna, S Terry, V Mistry… - American journal of …, 2012 - atsjournals.org
… Correspondence and requests for reprints should be addressed to Mona Bafadhel, MBCh.B.,
Institute for Lung Health, Clinical Sciences Wing, University Hospitals of Leicester, Leicester…
Institute for Lung Health, Clinical Sciences Wing, University Hospitals of Leicester, Leicester…
[HTML][HTML] Expression of the T helper 17-associated cytokines IL-17A and IL-17F in asthma and COPD
C Doe, M Bafadhel, S Siddiqui, D Desai, V Mistry… - Chest, 2010 - Elsevier
Background Asthma and COPD are characterized by airway dysfunction and inflammation.
Neutrophilic airway inflammation is a common feature of COPD and is recognized in asthma, …
Neutrophilic airway inflammation is a common feature of COPD and is recognized in asthma, …
[HTML][HTML] Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label …
LM Yu, M Bafadhel, J Dorward, G Hayward, BR Saville… - The Lancet, 2021 - thelancet.com
Background A previous efficacy trial found benefit from inhaled budesonide for COVID-19 in
patients not admitted to hospital, but effectiveness in high-risk individuals is unknown. We …
patients not admitted to hospital, but effectiveness in high-risk individuals is unknown. We …
Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials
M Bafadhel, S Peterson, MA De Blas… - The Lancet …, 2018 - thelancet.com
Background The peripheral blood eosinophil count might help identify those patients with
chronic obstructive pulmonary disease (COPD) who will experience fewer exacerbations when …
chronic obstructive pulmonary disease (COPD) who will experience fewer exacerbations when …
Lung microbiome dynamics in COPD exacerbations
Increasing evidence suggests that the lung microbiome plays an important role in chronic
obstructive pulmonary disease (COPD) severity. However, the dynamics of the lung …
obstructive pulmonary disease (COPD) severity. However, the dynamics of the lung …
Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study
…, ER Bleecker, RA Panettieri, M Bafadhel… - The Lancet …, 2014 - thelancet.com
Background Chronic obstructive pulmonary disease (COPD) is associated with eosinophilic
airway inflammation in 10–20% of patients. Benralizumab, an anti-interleukin-5 receptor α …
airway inflammation in 10–20% of patients. Benralizumab, an anti-interleukin-5 receptor α …